Biotechnology Following a positive recommendation from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in the spring (The Pharma Letter March 25), French drug major Sanofi (Euronext: SAN) and its subsidiary Genzyme announced on Friday (August 30) that the European Commission has granted marketing authorization for Aubagio (teriflunomide) 14mg, a once-daily, oral therapy indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS). 2 September 2013